Relapsed or refractory mantle cell lymphoma (r/r MCL)
Mantle cell lymphoma (MCL) is a rare and highly heterogeneous B‑cell non‑Hodgkin lymphoma (NHL) originating from the mantle zone of lymph nodes. In newly diagnosed MCL, the duration of response after first‑line standard therapy is short and the relapse rate is high; the median survival time after first‑line relapse is only 3‑4 years. The majority of patients still experience disease progression after treatment with BTK inhibitors, and the subsequent overall survival (OS) following progression is only 6‑10 months. Therefore, new therapies are urgently needed to improve response rates and long‑term survival in patients with MCL who have relapsed or become refractory after immunochemotherapy and BTK inhibitor treatment.
The JWCAR029-005 study (NCT0471883) is an open‑label, single‑arm, multicenter phase II study. In the JWCAR029-005 study1,2, 59 patients with r/r MCL after second line or above systemic treatment, including treatment with Bruton tyrosine kinase inhibitors were treated with relma-cel.
- Deep response: Relma‑cel achieved a CRR of 67.8% in patients previously treated with a BTK inhibitor (cBTKi)2
- Durable benefit: The median PFS with relma‑cel in cBTKi‑pretreated patients was 15.5 months2
- Tolerable safety: The incidence of serious adverse events with relma‑cel in r/r MCL patients was low2
Note: The data above comes from the RELIANCE study, individual patient may have different results of treatment in the clinical practice based on multiple factors, including physical condition, disease status, T cell function and so on. It is recommended that you can consult the healthcare professionals if you have specific questions.
1. https://clinicaltrials.gov
2. Xie Y, et al. Blood Adv 2026;10(4):1134-1144.